GlassScriptPhysician profile
Paul Hohman
NPI 1194105023
$696.77
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $221.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $130.20 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $119.49 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $93.39 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $81.53 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $76.67 | 2019-2020 | |
| Mylan Specialty L.P. | $53.84 | 2019-2020 | |
| Allergan, INC. | $47.63 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $30.84 | 2019 | |
| Portola Pharmaceuticals, LLC | $27.64 | 2019 | |
| Nabriva Therapeutics, Plc | $23.26 | 2020 | |
| Smith+Nephew, INC. | $12.28 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Hohman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.